Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL840146 | 0.75 | KDM4E (0.41) | KDM4ENPC1LMNAALOX15HTT | |
| SCHEMBL22920544 | 0.72 | KDM4E (0.39) | KDM4ENPC1LMNAALOX15HTT | |
| SCHEMBL24377495 | 0.66 | — | — | |
| SCHEMBL1109602 | 0.65 | LMNA (0.41) | KDM4ENPC1LMNAALOX15HTT | |
| SCHEMBL840387 | 0.65 | KDM4E (0.36) | KDM4ENPC1LMNAALOX15HTT | |
| SCHEMBL24733235 | 0.64 | KDM4E (0.41) | KDM4ENPC1LMNAALOX15HTT | |
| SCHEMBL12811721 | 0.64 | CHRNA7 (0.42) | KDM4ENPC1LMNAALOX15HTT | |
| SCHEMBL18843589 | 0.64 | KDM4E (0.41) | KDM4ENPC1LMNAALOX15HTT | |
| SCHEMBL841052 | 0.63 | KDM4E (0.35) | KDM4ENPC1LMNAALOX15HTT | |
| SCHEMBL24320169 | 0.62 | KDM4E (0.40) | KDM4ENPC1LMNAALOX15HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11179397-B2 | Imidazopyrimidine derivatives | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200108071-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200108071-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | DPYD, KRAS, ABL1 | KDM4E 2055/4885NPC1 394/4885LMNA 3865/4885 |
| US-11179397-B2 | Imidazopyrimidine derivatives | DPYD, KRAS, ABL1 | KDM4E 2055/4885NPC1 394/4885LMNA 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.